Industry transformers; it takes one to know one. Meet Rasmus.

In the world of innovation, the most impactful advancements often come from those willing to challenge the status quo. The partnership between IonOpticks, a leader in proteomics solutions, and Adelis Equity Partners , recognised for its differentiated investment strategies, exemplifies the potential success achievable when two industry transformers unite. Rasmus Molander , Co-Managing Partner of Adelis and a strong advocate for innovation, played a pivotal role in forging this partnership and was attracted by IonOpticks’ reputation for excellence and its unwavering commitment to innovation and efficient manufacturing capabilities.

Adelis is redefining the private equity landscape by challenging the conventional transactional approach, positioning itself as an industry transformer that prioritises partnerships and collaboration. For Rasmus, collaboration is key to building sustainable and resilient businesses.?

“With our investments, we are committed to cultural and strategic alignment, as it empowers us to drive innovation, growth and internationalisation across the companies within our portfolio,” Rasmus explains, emphasising the unique nature of Adelis’ investment philosophy that sets it apart from most private equity firms. ?

While Adelis primarily operates within the Nordics and Germany, its partnership with IonOpticks underscores the firm’s commitment to prioritising excellence over geography. Adelis seeks out companies that push boundaries in their fields, and IonOpticks stood out for its transformative impact on proteomics research, developing innovative solutions that help researchers extract more from their samples. IonOpticks aligns very well with Adelis’ vision of fostering innovation and driving growth, extending beyond location in pursuit of excellence.

The decision to partner with IonOpticks was also driven by its exceptional products and its dedication to delivering high-quality solutions at scale. Rasmus believes the company’s efficient manufacturing processes and unwavering focus on consistent quality provide a competitive advantage often underestimated in the industry.

“Manufacturing capabilities are crucial,” he emphasises. “Being able to produce high-quality products efficiently and at scale is what ultimately drives growth and IonOpticks is a prime example of this.”

Adelis was particularly drawn to IonOpticks’ rich culture, which was evident to those who work close to the company and its customers. “The culture of a company is defined by what it does, not what it says,” Rasmus reflects. Preserving IonOpticks’ strong culture as it grows is a priority for him and his team, ensuring that cultural integrity remains intact while fostering an environment that encourages performance, innovation and collaboration.

Rasmus envisions a future where IonOpticks continues to expand its global salesforce and accelerates research and development efforts. His goals include enhancing the compatibility of IonOpticks’ products with further mass spectrometry brands and streamlining production processes to meet the growing demands of the market.

As Rasmus Molander joins the board of directors at IonOpticks, the company is poised to effectively navigate future challenges while continuing its trajectory of growth and innovation. Together, they are dedicated to advancing the field of proteomics and making a meaningful impact on global health outcomes.

About Ramus.

Rasmus began his journey in the life sciences industry with a strong academic foundation, earning a MSc in Industrial Engineering and Biotechnology from the Helsinki University of Technology and a MBA from Harvard Business School. His early career saw him as an Investment Executive at Permira, a leading global private equity firm, where he specialised in healthcare. He also gained valuable experience as a consultant at the Boston Consulting Group (BCG).

In 2013 Rasmus joined Adelis Equity Partners, currently serving as co-managing partner, ?where he applies his expertise in healthcare investments and strategic growth to help businesses scale. He also holds extensive board experience across several companies, including SSI Diagnostica Group, Europa Biosite, Ropo, Puuilo, Re:mount, Valtti, QMG, and Med Group.

Rasmus is passionate about building businesses and helping them grow and internationalise, aligning with Adelis’ mission of investing in mid-sized firms and driving their expansion and development.